
Myeloma Paper of the Day, July 9th, Suggested by Robert Orlowski
Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Case report of the use of teclistamab for treatment of relapsed/refractory POEMS syndrome producing a durable biochemical and radiographic remission lasting past drug discontinuation and without any unanticipated toxicities.”
Title: Teclistamab for heavily pretreated relapsed/refractory POEMS syndrome
Authors: Alexis Talbot, Nathalie Forgeard, Tristan Vaugeois, Floriane Theves, Sabrine Dimassi, Bruno Royer, Pierre-Edouard Debureaux, Véronique Meignin, Laetitia Vercellino, David Boutboul, Bertrand Arnulf, Stéphanie Harel
You can read the Full Article in Haematologica.
You can find more posts featuring Robert Orlowski in OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023